CRBU (Caribou Biosciences) Construction In Progress: $0.00 Mil (As of Mar. 2026)


CRBU Caribou Biosciences Inc CRBU
65 GF Score
Price $1.76
GF Value $1.69
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Caribou Biosciences Construction In Progress?

Caribou Biosciences CRBU +0.57% 65 Construction In Progress is $0.00 Mil as of Mar. 2026. GuruFocus rates CRBU with a GF Score™ of 65/100 and a GF Value™ of $1.69 (Fairly Valued). The stock has 5 warning signs investors should review.

Caribou Biosciences's annual construction in progress declined from Dec. 2023 ($8.20 Mil) to Dec. 2024 ($0.00 Mil) but then stayed the same from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.00 Mil).

Caribou Biosciences Construction In Progress Historical Data

* Premium members only.

The historical data trend for Caribou Biosciences's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Caribou Biosciences Construction In Progress Chart

Caribou Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial 0.01 0.99 8.20 0.00 0.00

Caribou Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CRBU
65GF Score
Caribou Biosciences Inc CRBU
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Caribou Biosciences Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0.00 Mil mean?
Caribou Biosciences (CRBU) has a Construction In Progress of $0.00 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Caribou Biosciences and its competitors.
Is Caribou Biosciences' Construction In Progress too high?
Caribou Biosciences' current Construction In Progress is $0.00 Mil. Overall, Caribou Biosciences has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Caribou Biosciences' Construction In Progress compare to YDES and PRQR?
Caribou Biosciences' Construction In Progress of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Caribou Biosciences and its competitors. Caribou Biosciences's current Construction In Progress is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caribou Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Caribou Biosciences (CRBU) is currently considered Fairly Valued. The stock's GF Value™ is $1.69, compared to a current price of $1.76 — trading 4.1% above its estimated fair value. The current Construction In Progress is $0.00 Mil. Caribou Biosciences' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Caribou Biosciences (CRBU), the current Construction In Progress is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Caribou Biosciences (CRBU) Overvalued in 2026?

Based on GuruFocus' analysis, Caribou Biosciences stock appears to be overvalued. The current stock price of $1.76 is trading 4.1% above its estimated GF Value™ of $1.69. GuruFocus considers Caribou Biosciences to be Fairly Valued.

Key valuation signals for CRBU:

  • Construction In Progress: $0.00 Mil
  • GF Value™: $1.69 vs. price of $1.76 (4.1% above fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the CRBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Caribou Biosciences Business Description

Address 2929 7th Street, Suite 105, Berkeley, CA, USA, 94710
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
65GF Score

Get the complete analysis for CRBU

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.76
Price
$1.69
GF Value